Products - Skin cancer | Topic | NICE

Showing 8 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC